Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Becton Dickinson

One Recalled Saline Ampule Set Off a Cascade of Kit Recalls Reaching Thousands of American Hospitals

FDA has posted a run of early alerts and recalls involving convenience kits, most tracing back to recalled drug ampules and syringes.

Medical Daily

Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal

Becton Dickinson and Co (NYSE:BDX) reported fourth-quarter adjusted earnings of $3.96, beating the consensus of $3.92.

Benzinga

Becton, Dickinson and Company Stock: Is Wall Street Bullish or Bearish?

Despite Becton, Dickinson and Company’s weak performance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Becton Dickinson Q3 Beats Estimates On Medical Device Boom

As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company (NYSE:BDX) are reporting robust financial performances that highlight their resilience and strategic adaptability. The company’s stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.

Benzinga

3 Top-Rated Healthcare Stocks With 20% to 35% Upside Potential

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

Barchart

Stocks Settle Mixed as 10-Year T-note Yield Stays Above 4%

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.17%. Stocks on Tuesday settled mixed. Reduced expectations for...

Barchart

Becton Dickinson & Co. (BDX) Earnings Moves: A Buy or Sell for Investors?

Becton Dickinson & Co. (BDX) is expected to report steady growth for its fiscal fourth quarter ended September 2023, scheduled to be released on November 9. While the stock is witnessing weakness over the past month, will the quarterly report be able to spur a rally? Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

What Are Whales Doing With Becton, Dickinson

Someone with a lot of money to spend has taken a bearish stance on Becton, Dickinson (NYSE:BDX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

Upgrades

Benzinga

Death Cross Looms Over Becton, Dickinson Investors

If history is any guide, there may be trouble ahead for shares of Becton, Dickinson (NYSE:BDX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Looking Into Becton, Dickinson's Recent Short Interest

Becton, Dickinson's (NYSE:BDX) short percent of float has fallen 9.33% since its last report. The company recently reported that it has 3.87 million shares sold short, which is 1.36% of all regular shares that are available for trading.

Benzinga

$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,400 Today

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.98% on an annualized basis producing an average annual return of 12.93%. Currently, Becton, Dickinson has a market capitalization of $70.95 billion.

Benzinga

Analyst Ratings for Becton, Dickinson

Within the last quarter, Becton, Dickinson (NYSE:BDX) has observed the following analyst ratings:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022

Upgrades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Analyzing Becton, Dickinson's Short Interest

Becton, Dickinson's (NYSE:BDX) short percent of float has risen 11.94% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 1.5% of all regular shares that are available for trading.

Benzinga

Here's How Much You Would Have Made Owning Becton, Dickinson Stock In The Last 20 Years

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.34% on an annualized basis producing an average annual return of 10.37%. Currently, Becton, Dickinson has a market capitalization of $71.95 billion.

Benzinga

Becton Dickinson Buying Parata Systems - Read Why

Becton Dickinson and Co (NYSE:BDX) will acquire Parata Systems from Frazier Healthcare Partners for $1.525 billion. Parata offers a portfolio of pharmacy automation solutions to reduce costs, enhance patient safety and improve the patient experience. Significant macro trends such as clinician shortages, wage inflation, centralization of pharmacy services, and increased clinical demands…

Benzinga

$1000 Invested In Becton, Dickinson 10 Years Ago Would Be Worth This Much

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.48% on an annualized basis producing an average annual return of 13.59%. Currently, Becton, Dickinson has a market capitalization of $72.68 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Better Buy: Becton Dickinson vs. Intuitive Surgical

Growing demand for critical surgical procedures and increasing investments in R&D should drive the medical devices industry’s growth. Prominent medical device companies Becton Dickinson (BDX) and Intuitive Surgical (ISRG) are well-positioned to capitalize on the industry tailwinds. But which of these stocks is a better buy now? Read more to…

Benzinga

Expert Ratings for Becton, Dickinson

Over the past 3 months, 5 analysts have published their opinion on Becton, Dickinson (NYSE:BDX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Becton Dickinson Raises FY22 Guidance As Q2 Earnings Top Estimates

Becton Dickinson and Co (NYSE:BDX) reported Q2 FY22 revenues of $5.01 billion, up 2.1% Y/Y (3.9% on a currency-neutral basis), better than the consensus of $4.85 billion. Revenue was driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by the decline in COVID-only testing revenues to $214 million…

Benzinga

Becton, Dickinson: Q2 Earnings Insights

Becton, Dickinson (NYSE:BDX) reported its Q2 earnings results on Thursday, May 5, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Expert Ratings For Becton, Dickinson

Analysts have provided the following ratings for Becton, Dickinson (NYSE:BDX) within the last quarter:

StockNews.com

Baxter International vs. Becton Dickinson: Which Medical Equipment & Supply Stock is a Better Buy?

The demand for medical equipment & supplies is rising exponentially with the emergence of severe illnesses such as the ongoing Coronavirus pandemic and the growing elderly population. So, Baxter International (BAX) and Becton Dickinson and Company (BDX) should benefit. But which of these two stocks is a better buy now?…

Organisations

the Wall Street Journal

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Bitcoin

8,821 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.